Repros's Proellex trials put on hold due to safety concerns
This article was originally published in Scrip
Executive Summary
The US FDA has placed the INDs for Repros Therapeutics' Proellex (CDB-4124) on hold due to concerns that the drug increases liver enzyme levels, a sign of toxicity.